ReviewFrontiers in immunology2025
Thymic B cells in aging and autoimmune disease.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Fibroblast-driven collagen expansion and altered thymic medullary niches in 22q11.2 deletion syndrome.Journal of human immunity · 2026Article
- A Rasa3-Gαi signaling axis orchestrates B lymphocyte trafficking into and through lymphoid organs.Cell reports · 2026Article
- Unbiased recording and identification of thymic cellular interactomes using synthetic Notch receptors.Nature communications · 2026Article
- AIRE transcriptional condensates in central tolerance: a multiscale mechanistic perspective.Frontiers in immunology · 2026Review
- Radioresistant intrathymic stem cells: retrospective analysis and concept of the role in thymic oncogenesis and post-irradiation regeneration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Thymic B cells comprise a heterogenous population of cells localized primarily within the thymic medulla, a region populated by professional antigen-presenting cells (APCs) including dendritic cells, medullary thymic epithelial cells (mTECs), and macrophages. Through expression and presentation of self-antigens, these APCs are responsible for shaping the normal T cell repertoire by negatively selecting thymocytes recognizing self-antigens. It is now clear that thymic B cells have the capacity to participate in negative selection and present cognate antigens distinct from other medullary APCs, thus serving a non-redundant role in mediating T cell central tolerance. Recent work has linked thymic B cells with the development of multiple autoimmune diseases, many of which are increased in prevalence with aging. Here, we will provide a brief overview of the role of thymic B cell subsets in promoting negative selection and immune homeostasis, with a primary focus on the impact of aging on their tolerizing capacity and involvement in autoimmune diseases, highlighting thymic B cells as a potential novel therapeutic target to improve clinical outcomes in patients with autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.